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Summary
 
Src homology 2 (SH2) domain–containing phosphotyrosine phosphatases (SHPs) are increas-
ingly being shown to play critical roles in protein tyrosine kinase–mediated signaling pathways.
The role of SHP-1 as a negative regulator of T cell receptor (TCR) signaling has been estab-
lished. To further explore the function of the other member of this family, SHP-2, in TCR-
mediated events, a catalytically inactive mutant SHP-2 was expressed under an inducible
promoter in Jurkat T cells. Expression of the mutant phosphatase significantly inhibited
TCR-induced activation of the extracellular-regulated kinase (ERK)-2 member of the mito-
gen-activated protein kinase (MAPK) family, but had no effect on TCR-
 
z
 
 chain tyrosine phos-
phorylation or TCR-elicited Ca
 
2
 
1
 
 transients. Inactive SHP-2 was targeted to membranes re-
sulting in the selective increase in tyrosine phosphorylation of three membrane-associated
candidate SHP-2 substrates of 110 kD, 55-60 kD, and 36 kD, respectively. Analysis of immu-
noprecipitates containing inactive SHP-2 also indicated that the 110-kD and 36-kD Grb-2–asso-
ciated proteins were putative substrates for SHP-2. TCR-stimulation of Jurkat T cells express-
ing wild-type SHP-2 resulted in the formation of a multimeric cytosolic complex composed of
SHP-2, Grb-2, phosphatidylinositol (PI) 3
 
9
 
-kinase, and p110. A significant proportion of this
complex was shown to be membrane associated, presumably as a result of translocation from
the cytosol. Catalytically inactive SHP-2, rather than the wild-type PTPase, was preferentially
localized in complex with Grb-2 and the p85 subunit of PI 3
 
9
 
-kinase, suggesting that the de-
phosphorylating actions of SHP-2 may regulate the association of these signaling molecules to
the p110 complex. Our results show that SHP-2 plays a critical role in linking the TCR to the
Ras/MAPK pathway in Jurkat T cells, and also provide some insight into the molecular inter-
actions of SHP-2 that form the basis of this signal transduction process.
 
T
 
he increase in the tyrosine phosphorylation of multiple
cellular substrates as a result of the activation and re-
cruitment of Src and Syk/ZAP-70 family tyrosine kinases is
the critical, initiating event that couples the TCR to
downstream signaling pathways such as calcium mobili-
zation and the Ras–mitogen-activated protein kinase
(MAPK)
 
1
 
 pathway (1, 2). The transmembrane phosphoty-
rosine phosphatase (PTPase) CD45 positively regulates
these events at their origin by dephosphorylating p56
 
lck
 
 and
p59
 
fyn
 
, thereby maintaining these tyrosine kinases in their
active conformation (3–6). The actions of CD45-activated
p56
 
lck
 
 are required for the phosphorylation of the TCR-
 
z
 
chain, which is then engaged by Src homology (SH) 2–con-
taining kinases such as ZAP-70 and Syk (1, 6, 7).
The PTPase-mediated dephosphorylation of the numer-
ous proteins that become phosphorylated as a result of
TCR ligation remains poorly understood. T cells express the
SH2 domain–containing PTPases, SHP-1 and SHP-2, which
clearly have distinct roles. Thus, the motheaten mouse pa-
thology, which results from a lack of SHP-1 protein or en-
zymatic activity, develops in the context of normal levels of
SHP-2 expression (8, 9). Beyond their possession of two
SH2 domains and a PTPase domain, SHP-1 and SHP-2
have relatively low sequence homology and consequently
have the ability to bind to different phosphotyrosine-con-
taining proteins (10) and exhibit quite distinct substrate
specificities (11). SHP-1 negatively regulates signaling through
 
1
 
Abbreviations used in this paper:
 
 AEBSF, 4-(2-Aminoethyl)-benzenesulfo-
nylfluoride.HCl; csw, corkscrew; ERK, extracellular regulated kinase;
GST, glutathione 
 
s
 
-transferase; MAPK, mitogen-activated protein kinase;
MBP, myelin basic protein; PI, phosphatidylinositol; PTPase, phosphoty-
rosine phosphatase; SH2, Src homology 2; SHP, phosphotyrosine phos-
phatase.
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several hematopoietic receptors (12), and in T cells inhibits
TCR-mediated signal transduction, possibly by dephos-
phorylating ZAP-70 and/or p56
 
lck
 
 (13, 14). In addition,
the ubiquitously expressed SHP-2 has been proposed to act
as a negative regulator of T cell signaling based on its asso-
ciation with the coreceptor CTLA-4 (15). In contrast,
SHP-2 and its Drosophila homologue (corkscrew, or csw)
have been shown to positively regulate the transduction of
receptor-mediated signaling events leading to mitogenesis
and differentiation in both hematopoietic and nonhemato-
poietic systems (16–19). The expression of dominant-nega-
tive SHP-2 in a variety of studies has indicated a positive
role for this PTPase in regulating receptor coupling to the
Ras/MAP kinase pathway in growth factor responsive cells
(18, 20). We therefore endeavoured, using a perturbing
mutant strategy, to address the role of SHP-2 function in
TCR-mediated signaling in Jurkat T cells.
We have previously shown that SHP-2, but not SHP-1,
associates with a 110-kD (p110) tyrosine phosphoprotein
upon ligation of the TCR in Jurkat T cells (10). The tran-
sient tyrosine phosphorylation of p110 after receptor liga-
tion pointed to a possible role for the SHP-2–p110 com-
plex in TCR signal transduction. We now show that SHP-2
selectively regulates TCR-coupling to the Ras-MAP ki-
nase pathway in Jurkat T cells. A catalytically inactive ver-
sion of SHP-2 is preferentially targeted to membranes, re-
sulting in the increased tyrosine phosphorylation of
membrane-associated p110 and p36 proteins. SHP-2 is
found in a complex with Grb-2, phosphatidylinositol (PI)
3
 
9
 
-kinase, and a p110 tyrosine phosphoprotein that we dis-
tinguish from the recently described signal regulatory pro-
tein (SIRP) family of transmembrane proteins (21). This
complex becomes membrane associated, a cellular context
that may promote the dephosphorylating actions of SHP-2.
We propose that SHP-2 promotes coupling of the TCR to
the MAPK pathway by dephosphorylating phosphoty-
rosine residues in p110, a putative docking protein, thereby
regulating the Grb-2 and/or PI 3
 
9
 
-kinase content of a mul-
ticomponent signaling complex.
 
Materials and Methods
 
Cells, Cell Culture, and Stimulation.
 
The E6 Jurkat T cell line
was cultured in RPMI medium containing 5% FCS. The L cell
fibroblast cell line used was maintained in DMEM with 10%
FCS. Jurkat T cells were stimulated by addition of OKT3 for 1
min (for concentrations see figure legends).
 
Reagents.
 
The following were gifts: CD3 mAb (OKT3;
Cilag, Paris, France), TCR-
 
z
 
 antiserum (Dr. C. Terhorst, Har-
vard Medical School, Boston, MA), extracellular regulated kinase
(ERK)-2 antiserum (Dr. J. Saklatvala, Babraham Institute, Cam-
bridge, UK), DOS mAb (Dr. T. Raabe, University of Wurzburg,
Wurzberg, Germany), and SHP-2 antiserum (Dr. B. Neel, Beth
Israel Hospital, Boston, MA). pZEM neo plasmids were provided
by Dr. A. Saltiel, Parke-Davis Pharmaceuticals, Ann Arbor, MI.
A plasmid containing cDNA encoding glutathione 
 
s
 
-transferase
(GST)–Grb-2 was a gift from Dr. D. Cantrell, ICRF, London,
UK. The following commercially available antibodies were used:
SHP-2 antiserum (Santa-Cruz Biotechnology, Santa Cruz, CA)
 
PI 3
 
9
 
-kinase p85 antiserum (Upstate Biotechnology, Inc., Lake
Placid, NY), SHP-2 and Grb-2 mAbs (Transduction Labs, Lex-
ington, KY), and 4G10 phosphotyrosine mAb (Upstate Biotech-
nology, Inc.).
 
Generation of Dominant-negative (PTPase-inactive) SHP-2–express-
ing Cells.
 
Jurkat T cells were electroporated in the presence of
empty expression vector containing the human metallothionein
promoter and neomycin resistance gene (pZEM neo) or the same
vector containing an insert encoding point mutated (cysteine
 
459
 
to serine) SHP-2 protein (18). Clonal cell lines were isolated by
selection in 1.5 mg/ml G418 (Sigma Chemical Co., St. Louis,
MO). Expression of mutant SHP-2 (C
 
®
 
S SHP-2) was induced
by a 5-h treatment with 10 
 
m
 
M cadmium and assayed by immu-
noblotting. C
 
®
 
S SHP-2 and vector control clones were matched
for CD3 expression by Kolmogorov-Smirnov statistical analysis
of FACS
 
Ò
 
 (Becton Dickinson, Mountain View, CA) data.
 
Immunoprecipitation and Immunoblot Analysis.
 
Before stimula-
tion, Jurkat T cells (10
 
7
 
) were washed and maintained under se-
rum-free conditions for 5 h. After stimulation cells were lysed
in 0.5 ml of lysis buffer (1% NP-40, 10 mM Tris-HCl, pH 7.5,
150 mM NaCl, 50 mM NaF, 20 mM
 
 tetra
 
-sodium pyrophos-
phate, 1 mM sodium orthovanadate, 2 
 
m
 
g/ml aprotinin and leu-
peptin, 1 mM [4-(2-aminoethyl)-benzenesulfonylfluoride.HCl],
or AEBSF, 1 mM EGTA, and 10 mM EDTA).
Electrophoretic mobility shift assays for ERK-2 were per-
formed on postnuclear cell lysates. Samples were separated on
10% gels for 24 h to achieve clear resolution of phosphorylated
and nonphosphorylated ERK-2. After transfer to Immobilon-P
membrane, the samples were probed with ERK-2 polyclonal an-
tibody.
For immunoprecipitation of SHP-2, TCR-
 
z
 
 chain, ERK-2,
and PI 3
 
9
 
-kinase p85, protein A–precleared cell lysates were
mixed with sepharose-bound antibody for 2 h at 4
 
8
 
C. Adsorption
of Jurkat T cell lysates to GST fusion proteins was carried out un-
der the same conditions. Wild-type and mutant SHP-2 were in-
dependently precipitated as follows: wild-type SHP-2 was re-
moved from mutant-expressing cell lysates using an antibody
specific for the COOH terminus, and immunoprecipitates of mu-
tant SHP-2 were then prepared using an antibody that recognized
both wild-type and mutant SHP-2 from the depleted lysates. Pre-
cipitates were washed rigorously, subjected to SDS-PAGE, and
transferred to Immobilon
 
 P 
 
membrane. Immunoblot analysis us-
ing phosphotyrosine, SHP-2, Grb-2, p85, and ERK-2 antibodies
was performed using the ECL detection system (Amersham Life
Sciences Ltd., Little Chalfont, UK). Immunoblots shown are each
representative of 3–4 independent experiments. Quantitation of
ECL signals was measured using a Bio-Rad chemiluminescence
screen (Bio-Rad, Hercules, CA) and GS-525 Molecular Imager
System (Bio-Rad).
 
In Vitro Kinase Assay.
 
ERK-2 immunoprecipitates were
washed in PBS and mixed continuously for 30 min at room tem-
perature in 30 mM Tris-HCl, 20 mM MgCl
 
2
 
, 2 mM MnCl
 
2
 
, 5 
 
m
 
M
ATP, 8 
 
m
 
g myelin basic protein (MBP), and 5 
 
m
 
Ci 
 
g
 
-[
 
32
 
P]ATP.
Samples were subjected to SDS-PAGE and analyzed by autoradi-
ography.
 
Subcellular Fractionation.
 
Control or stimulated Jurkat T cells
(2 
 
3 
 
10
 
7
 
) were resuspended in 1 ml homogenization buffer (20
mM Hepes, pH 7.5, 5 mM sodium pyrophosphate, 5 mM
EGTA, 1 mM Mg
 
2
 
Cl, 1 mM AEBSF, 10 
 
m
 
g/ml aprotinin and leu-
peptin, and 1 mM sodium orthovanadate) and sonicated three
times at 10% of full power. The resulting homogenate was centri-
fuged at 12,000 
 
g
 
 for 1 min to remove unbroken cells and the nu-
clear pellet. The supernatant was then centrifuged at 100,000 
 
g 
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for 60 min and the membrane pellet and supernatant (soluble
fraction) were collected. The pellet was washed, resuspended in
1 ml extraction buffer (20 mM Tris-HCl, pH 7.5, 1% Triton X-100,
100 mM NaCl, 1 mM MgCl
 
2
 
, 1 mM CaCl
 
2
 
, 5 mM NaF, 1 mM
AEBSF, and 1 mM sodium orthovanadate) and rotated for 60 min.
The suspension was then centrifuged at 100,000 
 
g
 
 for 45 min and
the detergent-soluble extract was recovered in the supernatant
(membrane fraction). All steps were conducted at 4
 
8
 
C. For subse-
quent immunoprecipitations, the soluble fraction samples were
supplemented with NaCl and detergent to equivalence with
membrane fraction samples.
 
Results and Discussion
 
SHP-2 Regulates TCR-stimulated ERK-2 Activation in Jur-
kat T Cells.
 
PTPases contain an essential catalytic cysteine
residue, the mutation of which results in a catalytically in-
active enzyme, which still binds, but does not hydrolyze,
tyrosine phosphate. This inactive PTPase can act as a dom-
inant negative inhibitor of tyrosine dephosphorylation in
vitro by binding specific phosphotyrosine residues, subse-
quently blocking dephosphorylation by the wild-type phos-
phatase. Mutation of Cys 459 to Ser in SHP-2 is known to
ablate catalytic activity of the protein (18). Jurkat T cells
were therefore stably transfected with cDNA encoding cat-
alytically inactive SHP-2. Expression of mutant protein
(C
 
®
 
S SHP-2) was controlled by a metallothionein pro-
moter and induced by the addition of cadmium. The cad-
mium-inducible SHP-2 in Jurkat T cells consistently mi-
grated at 69 kD rather than 72 kD (Fig. 1 
 
A
 
, 
 
top
 
). The
69-kD inducible form was no longer recognized by an an-
tibody specific for the SHP-2 COOH terminus (data not
shown), suggesting the selective loss of a small COOH-ter-
minal peptide 
 
z
 
30 residues in length from the C
 
®
 
S ver-
sion of the enzyme. The integrity of the cDNA used in
these studies was confirmed by the fact that transfected fi-
broblasts expressed cadmium-inducible full length C
 
®
 
S
SHP-2 (data not shown). Although the truncation resulted
in the loss of a putative Grb-2 binding site in the mutant
SHP-2, the relevance of this interaction in T cells is nulli-
fied by the lack of tyrosine phosphorylation on SHP-2 ob-
served upon TCR ligation in these cells (10). We surmised
that the COOH terminus deletion of C
 
®
 
S SHP-2 did not
extend into the PTPase domain and therefore should not
affect the ability of the protein to bind to its substrate and
hence act as a dominant negative.
We therefore assessed the effect of the expression of this
inactive enzyme on TCR-stimulated ERK-2 activation.
Fig. 1 
 
A 
 
(
 
middle
 
) shows that expression of C
 
®
 
S SHP-2 re-
sulted in an inhibition of TCR-stimulated ERK-2 phos-
phorylation as measured by an electrophoretic mobility
shift assay. This inhibition was observed in four indepen-
dently isolated clones and was reproducibly greater than the
small inhibition of TCR-induced signaling caused by the ad-
dition of cadmium alone (Fig. 1, 
 
A 
 
and 
 
C
 
). The TCR-
induced increase in ERK-2 activity, as measured by the
phosphorylation of MBP, was similarly affected by expres-
sion of mutant SHP-2 (Fig. 1 
 
A
 
, 
 
bottom
 
). Quantitation from
four separate experiments on a single clone revealed that
ERK-2 activation was inhibited by 39 
 
6 
 
8% when C
 
®
 
S
SHP-2 expression was 50% of total SHP-2. The degree of
inhibition observed in each clone correlated well with the
amount of mutant SHP-2 protein expressed relative to the
endogenous enzyme (Fig. 1 
 
B
 
). The modest C
 
®
 
S SHP-2
expression level achieved with this system (18) made it un-
likely that the mutant PTPase perturbed pathways unre-
lated to the actions of SHP-2. Inhibition was selective since
tyrosine phosphorylation of the TCR-
 
z
 
 chain was unaf-
fected by expression of C
 
®
 
S SHP-2 (Fig. 1 
 
C
 
), which had
no discernible effect on TCR-
 
z
 
 phosphorylation at either
minimal (0.1 
 
m
 
g/ml) or maximal (1 
 
m
 
g/ml) concentrations
of TCR agonist (data not shown). Likewise, catalytically-
inactive SHP-2 did not affect TCR-stimulated rises in in-
tracellular Ca
 
2
 
1
 
 (data not shown).
Despite the inhibition of TCR-induced ERK-2 activa-
tion, IL-2 secretion in these cells was not significantly af-
fected by expression of mutant SHP-2 (data not shown).
However, the interpretation of such data is confounded by
the requirement for phorbol ester and ionomycin in con-
junction with CD3 mAb to observe measurable IL-2 secre-
tion in Jurkat T cells. Similarly, this cocktail of stimuli was
necessary to observe IL-2 gene induction using a green flu-
orescent protein-linked reporter in transient transfection
assays (data not shown). Since phorbol-ester–activated pro-
tein kinase C powerfully drives activation of the Ras/
MAPK pathway by a tyrosine kinase–independent mecha-
nism (22), it is possible that the effects of mutant SHP-2
may not be revealed using such protocols. Therefore, a
transgenic mouse approach is being used to address the role
of SHP-2 in regulating IL-2 secretion in primary T cells,
whereas the Jurkat T cell system has been used in the
present work to investigate the molecular interactions and
potential substrates of SHP-2 and elucidate how SHP-2 is
involved in more proximal TCR signaling events.
 
SHP-2 Acts Primarily at the Membrane.
 
In nonhemato-
poietic cells in which the PTPase activity of SHP-2 has
been demonstrated as necessary for receptor-stimulated
MAPK activation, the actions of this PTPase and thereby
its substrate(s) have been placed upstream of Ras (23–25).
The initiation of the Ras-MAPK pathway occurs at the
plasma membrane, where GTP-loaded Ras activates the
Raf-1 kinase (26). Interestingly, the activity of the SH2 do-
main PTPases is also increased by certain phospholipid en-
vironments (27). In an attempt to understand how SHP-2,
normally a cytosolic protein, might regulate membrane-
localized events, we investigated the subcellular distribution
of wild-type and catalytically inactive SHP-2. In TCR-
stimulated Jurkat T cells, a small percentage (estimated to
be 2%) of wild-type PTPase was reproducibly found in the
membrane fraction (Fig. 2 
 
A
 
). In a C
 
®
 
S SHP-2–express-
ing clone, in which the ratio of wild-type to mutant SHP-2
was 1:1, fractionation studies revealed that there was ap-
proximately twofold more mutant SHP-2 than endogenous
enzyme in the membrane fraction, whereas mutant SHP-2
constituted only 34% of total cytosolic SHP-2 (Fig. 2 
 
A
 
). 
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These data suggest that the catalytically inactive SHP-2 was
being trapped in membranes due to stable association with
its substrate(s). Indeed in membrane fractions in which cat-
alytically inactive SHP-2 was present in excess to endoge-
nous PTPase, three hyperphosphorylated proteins, 110 kD,
55/60 kD doublet, and 36 kD, were evident when com-
pared with an equivalent fraction prepared from vector
control cells (Fig. 2 
 
B
 
). The phosphorylation of these pro-
teins was increased by 1.3-, 1.6-, and 1.5-fold, respectively,
when compared with TCR-stimulated cells expressing
only endogenous SHP-2. In contrast, the phosphorylation
of two other membrane-associated tyrosine phosphopro-
teins, migrating on either side of the 74 kD marker, was
unaffected. The fact that catalytically inactive SHP-2 may
affect the phosphorylation state of more than one protein
implies that wild-type SHP-2 dephosphorylates several
components of a single signaling complex, or that this PTPase
regulates the activity of a kinase in this complex which
then changes the phosphorylation state of adjacent sub-
strates.
 
SHP-2–associated p110 Is the Major Putative SHP-2 Sub-
strate in Jurkat T Cells.
 
We have previously shown that
SHP-2 associates with a 110-kD tyrosine phosphoprotein
(p110) upon ligation of the TCR in Jurkat T cells p110
(10). The COOH-terminal truncation of mutant SHP-2 in
the present study has enabled the selective immunoprecipi-
tation of wild-type and catalytically inactive SHP-2 (see
Materials and Methods for details). Initial experiments sug-
gested that immunocomplexes of mutant SHP-2 demon-
strated stronger p110 phosphotyrosine signals than did im-
munocomplexes of wild-type SHP-2 (data not shown).
These experiments were carried out by sequentially precip-
itating the two versions of SHP-2 from the same lysate
sample using different antibodies. The interpretation of
such data are complicated by the use of antibodies raised to
distinct regions of SHP-2, which may themselves have in-
trinsic influences on the nature/quantity of proteins that
coprecipitate with SHP-2. We therefore designed an ex-
periment (see Materials and Methods for details), in which
wild-type and catalytically inactive SHP-2 were immuno-
precipitated, using the same antibody, from vector control
and C
 
®
 
S mutant-expressing lysates, respectively (Fig. 3 
 
A
 
).
In agreement with preliminary findings, Fig. 3 
 
A
 
 shows
that the phosphotyrosine signal derived from SHP-2–asso-
 
Figure 1.
 
Expression of catalytically inactive (C
 
®
 
S) SHP-2 inhibits
TCR-stimulated ERK-2 activation but not TCR-
 
z
 
 tyrosine phosphory-
lation in Jurkat T cells. pZEM neo C
 
®
 
S SHP-2 and empty vector trans-
fectants, matched for CD3 expression by FACS
 
Ò
 
 analysis, were incubated
for 5 h in the presence or absence of 10 
 
m
 
M cadmium. Cells were then
left untreated or were stimulated with TCR agonist (OKT3) at 0.5 
 
m
 
g/ml
for 1 min before lysis. (
 
A
 
) Aliquots of cell lysates (10
 
6
 
 cell equivalents)
 
were separated by SDS-PAGE and immunoblotted for SHP-2 (
 
top
 
) and
ERK-2 (
 
middle
 
). Alternatively, ERK-2 immunoprecipitates derived from
the indicated cell lysates were subjected to in vitro kinase assay using
MBP as a substrate (
 
bottom
 
). (
 
B
 
) Percentage of inhibition of TCR-stimu-
lated ERK-2 phosphorylation was measured in six different clones ex-
pressing different levels of mutant SHP-2 expression. (
 
C
 
) TCR-
 
z
 
 was
immunoprecipitated from lysates prepared as above, analyzed by SDS-
PAGE, and immunoblotted for phosphotyrosine. Numerical data shown
represent phosphorimager quantification of TCR-
 
z
 
 tyrosine phosphoryla-
tion upon TCR ligation in vector and mutant expressing clones and are
expressed as percentage of control 
 
6
 
 SEM (
 
n
 
 5 4); control 5 no addition
of cadmium.1421 Frearson and Alexander
ciated p110 was threefold greater when in complex with
catalytically inactive SHP-2 compared with wild-type. This
was evident under both basal and stimulated conditions.
The simplest explanation for the increased immunoprecipi-
tation of p110 in complex with mutant SHP-2 is that p110
is a substrate for SHP-2 and becomes trapped by the cata-
lytically inactive mutant, preventing it from being dephos-
phorylated by the wild-type PTPase. In the absence of an
antibody to p110 we cannot assume that p110 bound to in-
active SHP-2 is hyperphosphorylated, although this is an
attractive possibility.
To determine if the membrane-associated increases in
tyrosine phosphorylation illustrated in Fig. 2 B were specif-
ically SHP-2–related, we immunoprecipitated total SHP-2
from soluble and membrane fractions prepared from TCR-
stimulated control or mutant-expressing cells and analyzed
the samples for phosphotyrosine content (Fig. 3 B, top). In
agreement with the findings using whole fractions (Fig.
2 A), membranes contained disproportionately high levels
of catalytically inactive SHP-2 (Fig. 3 B, bottom). Impor-
tantly, immunocomplexes containing mutant SHP-2 from
membrane fractions had increased levels of two coprecipi-
tating proteins, p110 and p36, when compared with those
prepared from control cells. The p55/p60 tyrosine phos-
phoprotein observed in whole membrane fractions from
mutant-expressing cells (Fig. 2 B) was not observed in
SHP-2 immunoprecipitates, although it may have been ob-
scured by the immunoglobulin heavy chain signal.
SHP-2–associated p110 Is Not a SIRP. The SHP-2–associ-
ated p110 tyrosine phosphorylated protein in Jurkat cells
has not yet been identified. An immunodepletion strategy
of likely candidates has excluded c-cbl, cas, HRS-1, SLAP-
130, and PYK2. We have been unable to detect the ex-
pression of GAB-1, another likely candidate, in Jurkat cells
(data not shown). In terms of its ability to associate with
SHP-2 and its characteristic broad electrophoretic mobility
(10), Jurkat p110 is strikingly similar to a member of a re-
cently discovered family of novel docking proteins known
as SHPS-1 or SIRPs (signal-regulatory proteins) (21, 28).
This family has been shown to have negative regulatory ef-
fects on cellular responses by growth factors and onco-
genes. SIRPs are thought to serve as substrates for SHP-2
and have been proposed to act by sequestering the posi-
tively acting PTPase away from critical signaling com-
plexes. The members of this family are all glycosylated, re-
ceptor-like transmembrane proteins. In contrast, Fig. 3 B
shows that SHP-2–associated p110 was detected, in its ty-
rosine phosphorylated form, in both cytosolic and membrane
fractions of Jurkat cells. Furthermore, unlike members of
the SIRP family, the migration of p110 upon SDS-PAGE
analysis was unaffected by in vitro deglycosylation or upon
treatment of cells with tunicamycin in vivo (data not
Figure 2. Catalytically inac-
tive SHP-2 locates more effec-
tively to membranes than does
wild-type SHP-2, and it in-
creases membrane-associated
protein tyrosine phosphorylation.
(A) pZEM neo C®S SHP-2 and
empty vector transfectants were
incubated for 5 h in the presence
of 10 mM of cadmium and were
stimulated for 1 min with OKT3
(0.5  mg/ml). After sonication,
the resulting fractions were ana-
lyzed by SDS-PAGE and immu-
noblotted for SHP-2. To achieve
similar strength signals for accu-
rate quantitation, 10-fold less cell
equivalents of the soluble frac-
tion were loaded. The numerical
data shown represent quantitation of the amount of C®S SHP-2 present
in each fraction expressed as a percentage of total SHP-2 (wild-type 1
mutant) 6 SEM (n 5 3). (B) Membrane and soluble fractions prepared
from activated (0.5 mg/ml OKT3 for 1 min) vector control or C®S
SHP-2–expressing clones were analyzed by SDS-PAGE and immuno-
blotted for phosphotyrosine.
Figure 3. Expression of catalyti-
cally-inactive SHP-2 increases the
coprecipitation of two tyrosine
phosphorylated proteins, p110 and
p36, with SHP-2. (A) pZEM neo
C®S SHP-2 and empty vector
transfectants were incubated for 5 h
in the presence of 10 mM of cad-
mium and were left untreated or
were stimulated for 1 min with OKT3 (0.5 mg/ml) and lysed. Wild-type
(lanes 1 and 2) or mutant (C®S) SHP-2 (lanes 3 and 4) was immunopre-
cipitated from the relevant lysates (see Materials and Methods for details),
analyzed by SDS-PAGE and immunoblotted for phosphotyrosine (top)
and SHP-2 (bottom). (B) pZEM neo C®S SHP-2 and empty vector trans-
fectants were incubated for 5 h in the presence of 10 mM of cadmium and
then stimulated for 1 min with OKT3 (0.5 mg/ml). After sonication and
fractionation, total SHP-2 was immunoprecipitated from the indicated
fractions. The samples were analyzed by SDS-PAGE and immunoblotted
for phosphotyrosine (top) and then reprobed for SHP-2 (bottom).1422 SHP-2 Function in T Cells
shown). It is possible that the p110 protein found in T cells
is related to the recently reported SHP-2–associating pro-
teins p97 and p100 found in other (non–T cell) hemato-
poietic cell lines (29, 30).
Since SHP-2–associated p110 is not glycosylated, the
broad electrophoretic nature of this protein is therefore
likely to be due to multiple states of tyrosine phosphoryla-
tion, suggesting that it may act as a ‘docking protein’ similar
to IRS-1/2, GAB-1, or Dos (31–33). Dos is the 115-kD
substrate for the Drosophila homologue of SHP-2, known
as corkscrew (csw; reference 34) and contains proline-rich
sequences, an NH2-terminal pleckstrin homology domain,
and multiple potential tyrosine phosphorylation sites. Dos
is thought to be responsible for the activation of SHP-2, its
translocation to membranes, and its subsequent interaction
with components of the Ras-MAPK pathway. Although
the Jurkat p110 was not recognized by an authentic Dro-
sophila Dos mAb (data not shown), our biochemical data
suggest that p110 may be the mammalian equivalent of Dos
and this possibility is currently under investigation.
Tyrosine Phosphorylation of p36 Grb-2 Binding Protein Is
also Regulated by SHP-2. Fig. 3 B illustrates a SHP-2–associ-
ated p36 tyrosine phosphoprotein signal that was detectable
only when mutant SHP-2 was present in the immunocom-
plex. This interaction was particularly striking in mem-
branes considering the relatively low levels of SHP-2 pre-
cipitated from this fraction. A hyperphosphorylated p36
tyrosine phosphoprotein was also observed in whole mem-
brane fractions containing mutant SHP-2 (Fig. 2 B). p36
was identified as the Grb-2–binding protein (35) since it
bound effectively to a GST–Grb-2 fusion protein in vitro
(data not shown). Although formal identification is neces-
sary, p36 is very likely to be the recently cloned linker for
activation of T cells (LAT). LAT is a putative transmem-
brane protein with nine potential phosphotyrosine residues
(36), and is proposed to act as a binding module for SH2
domain–containing proteins such as Grb-2, PLCg1, and PI
39-kinase in TCR-stimulated T cells (35–37). Its state of
phosphorylation is critical to the propagation of signals
leading to transcriptional activation of nuclear factor of ac-
tivated T cells and activation protein 1 (36). The relatively
small proportion of total cellular p36 that coprecipitates
with mutant SHP-2 suggests that SHP-2 regulates the ty-
rosine phosphorylation of a select pool of this protein. Site
Figure 4. Grb-2, SHP-2, and p110 tyrosine phosphoprotein form a complex in TCR-activated Jurkat T cells. (A) Parental Jurkat T cells were stimu-
lated for 1 min with 0.5 mg/ml OKT3 and were lysed. The resulting lysates were subjected to two rounds of precipitation with GST or GST–Grb-2 fu-
sion proteins followed by immunoprecipitation of SHP-2. The resulting precipitates and sample aliquots of fusion protein-treated lysates (105 cell equiv-
alents) were analyzed by SDS-PAGE and immunoblotted for phosphotyrosine (top) and then reprobed for SHP-2 (bottom). (B) Parental Jurkat T cells
were left untreated or stimulated for 1 min with OKT3 (1 mg/ml) before sonication and fractionation. SHP-2 was immunoprecipitated from soluble and
membrane fractions, analyzed by SDS-PAGE and immunoblotted for phosphotyrosine (top) and reprobed for SHP-2 (middle) and Grb-2 (bottom). (C)
pZEM neo C®S SHP-2 and empty vector transfectants were incubated for 5 h in the presence of 10 mM cadmium and were stimulated for 1 min with
OKT3 (0.5 mg/ml) and lysed. The resulting lysates were mixed with immobilized GST–Grb-2 and the resulting precipitates then analyzed on SDS-PAGE
and immunoblotted for phosphotyrosine (top) and SHP-2 (bottom).1423 Frearson and Alexander
mapping and follow-up mutagenesis-function studies on
p36 will be necessary to elucidate the consequences of
SHP-2 action on this protein.
Grb-2, SHP-2, and p110 Tyrosine Phosphoprotein Form a
Complex in TCR-activated Jurkat T Cells. Dos has consen-
sus sequence SH2 domain binding sites for a number of sig-
naling proteins besides SHP-2, including Grb-2 and the
p85 subunit of PI 39-kinase (33). It is possible that the de-
phosphorylating actions of SHP-2 on such a docking pro-
tein may affect the localization and effectiveness of other
signaling molecules in this complex. Since we believe that
p110 may be a mammalian equivalent of Dos the associa-
tion of Grb-2 with the SHP-2–p110 complex was investi-
gated using a GST fusion protein of full-length Grb-2 (Fig.
4 A). Several tyrosine phosphoproteins from TCR-stimu-
lated Jurkat cells, including p36, p76, and a range of ty-
rosine phosphoproteins migrating between 100 and 130 kD
were found to associate with Grb-2, consistent with previ-
ous reports (38, 39). TCR-stimulated Jurkat cells were sub-
jected to two rounds of depletion with GST–Grb-2, or
GST as a control, and subsequent SHP-2 immunoprecipi-
tates then immunoblotted for phosphotyrosine. As illus-
trated in Fig. 4 A (top) no SHP-2–associated p110 was de-
tected in lysates previously depleted of Grb-2 binding
proteins, whereas p110 was clearly detected in control
GST-treated lysates, indicating that a complex between
p110, SHP-2, and Grb-2 exists in TCR-stimulated Jurkat
T cells. In accordance with this suggestion, Grb-2 was
found to coprecipitate with SHP-2 (Fig. 4 B, bottom). The
amount of Grb-2 detected in SHP-2 immunoprecipitates
increased upon TCR ligation (Fig. 4 B). Since it was ap-
parent that SHP-2 acted mainly on membrane substrates
(Fig. 2 B), we investigated the cellular compartmentation
of this complex. Fig. 4 B shows that despite the fact that
between 5- and 10-fold less SHP-2 was precipitated in the
membrane versus the cytosolic fraction, the p110 tyrosine
phosphorylation and Grb-2 protein levels were strikingly
equivalent between the two fractions. The higher stoichi-
ometry of the components of this complex in the mem-
brane compared with the cytosol may indicate that the
complex forms in the cytosol and then translocates as a unit
to the membrane. This hypothesis is corroborated by the
fact that there is an overall increase in the amount of SHP-2
detectable in the membrane fraction upon TCR ligation
(Fig. 4 B, middle).
The presence of Grb-2 in this complex is likely to bring
other Grb-2–associated molecules into the microenviron-
ment of SHP-2 and may explain the hyperphosphorylation
of p36, the major Grb-2 SH2 domain binding protein, in
Jurkat T cells expressing catalytically inactive SHP-2 (Fig.
2 B). p36 may prove to be the anchor responsible for re-
cruiting the SHP-2–p110–Grb-2 complex to the mem-
brane. It was notable that we were unable to detect any of
the known SH3 domain–mediated Grb-2–binding proteins
such as SLP-76, Sos, or c-cbl in SHP-2 immunocomplexes
(data not shown). This suggests that the SHP-2–p110 com-
plex contains a select pool of Grb-2 having SH3 domains
already occupied by proline-rich sequences in p110, con-
sistent with findings on a similar SHP-2–based signaling
complex recently described in IL-3–stimulated BaF3 cells
(40). We were interested in determining whether the asso-
ciation of Grb-2 with this complex would be affected by
the presence of catalytically inactive SHP-2. Fig. 4 C (top)
shows that the p110 protein precipitated with a GST–Grb-2
fusion protein was hyperphosphorylated in cells expressing
the C®S mutant. SHP-2 immunoblot analysis of these
precipitates demonstrated that more mutant than wild-type
SHP-2 bound to Grb-2 (Fig. 4 C, bottom). This observation
suggests that p110 in complex with mutant SHP-2 binds
Grb-2 more efficiently than does p110 associated with
wild-type PTPase, and may indicate that the actions of
SHP-2 can regulate the Grb-2 content of the complex.
The precise consequences of the adaptor function of Grb-2
in TCR-mediated cell signaling pathways have yet to be
elucidated.
PI 39-kinase, SHP-2, and p110 Form a Complex in TCR-
activated Jurkat T Cells. By analogy with the Drosophila
system, Dos also has a putative binding motif for the SH2
domains of the p85 subunit of PI 39-kinase (p85). Immu-
noprecipitation of p85 from TCR-stimulated Jurkat T cells
resulted in the coprecipitation of a striking tyrosine phos-
phoprotein that comigrated with SHP-2–associated p110
(Fig. 5 A, top). Two other groups have recently reported
the interaction of PI 39-kinase via the SH2 domains of its
p85 subunit with a p100 tyrosine phosphoprotein in he-
matopoietic growth factor signaling (29, 40). Prior deple-
tion of TCR-stimulated Jurkat lysates with p85 antibody
resulted in the loss of SHP-2–immunoprecipitable p110
(Fig. 5 A, top). Fig. 5 A (bottom) also illustrates that SHP-2
can be detected in p85 immunoprecipitates from TCR-
activated cells. The subcellular localization of p85-precipita-
ble p110 correlated well with that of SHP-2–p110 (data
not shown). These data indicate that the same p110 ty-
rosine phosphoprotein coprecipitates with both SHP-2 and
p85 and that all three proteins are likely to be in a complex
together. Interestingly, a small quantity of p36 was repro-
ducibly observed in p85 precipitates (Fig. 5 A, top), rein-
forcing the concept of a single multicomponent signaling
complex containing SHP-2, PI 39-kinase, p36, and p110.
Fig. 5 B (top) shows that the p110 that coprecipitated with
p85 from mutant SHP-2 expressing cells gave a consider-
ably stronger phosphotyrosine signal (1.7-fold) than that from
cells expressing only wild-type SHP-2. Analysis of these pre-
cipitates for SHP-2 content revealed an activation-depen-
dent coprecipitation of wild-type SHP-2 with p85 and, in
mutant-expressing cells, an increased propensity for inac-
tive SHP-2 rather than wild-type PTPase to be present in
the complex (Fig. 5 B, bottom). In accordance with the basal
phosphorylation of p110 in p85 immunoprecipitates pre-
pared from mutant-expressing cells, a constitutive level of
mutant SHP-2 was reproducibly observed in this sample
(Fig. 5 B, bottom). These observations presumably reflect
the trapping of inactive SHP-2 in the complex; the effect
of this upon PI 39-kinase content or activity of the com-1424 SHP-2 Function in T Cells
plex remains to be elucidated. However, it is interesting to
note that PI 39-kinase activation in response to insulin has
been shown to be sensitive to the expression of catalytically
inactive SHP-2 (41).
We therefore propose that Jurkat p110 acts as a cytosolic
docking protein that is responsible for the orchestration of a
signaling complex containing SHP-2, Grb-2, and PI 39-kinase,
which in turn regulates the positive actions of SHP-2 on
TCR coupling to the MAPK pathway, as illustrated in Fig.
6. The dephosphorylating actions of SHP-2 appear to take
place primarily in association with membranes since the
C®S SHP-2 mutant localizes there preferentially compared
with wild-type PTPase (Fig. 2 A) and the effects of mutant
SHP-2 on protein tyrosine phosphorylation are more
marked in the membrane fraction (Fig. 2 B). An attractive
model consistent with our results suggests that TCR-induced
tyrosine phosphorylation and conformational changes within
p110 provide binding sites for SHP-2, PI 39-kinase, and
Grb-2. The tyrosine phosphorylation of the p36 protein
may provide a membrane-localized docking site for the
complex via its reported interaction with the SH2 domain
of Grb-2. By analogy with other docking proteins such as
Dos, a putative pleckstrin homology domain in p110 could
also be involved in targeting or stabilizing the SHP-2–Grb-
2–PI 39-kinase–p110 complex in the plasma membrane.
The occupation of both SH2 domains of SHP-2 is neces-
sary for its full activation (42) yet only the COOH-termi-
nal domain is efficiently occupied by p110 (10). This inter-
action may serve solely to localize SHP-2 to the plasma
membrane where it may then associate with a phosphoty-
rosine residue that occupies its NH2-terminal SH2 domain,
thereby activating the enzyme. The phospholipid environ-
ment of the membrane may also be important for ensuring
that SHP-2 PTPase activity is preferentially directed to
membrane-associated substrates. Our results suggest that one
of these substrates is the SHP-2–associated p110 itself since,
first, a hyperphosphorylated 110-kD protein was demon-
strated in membrane fractions prepared specifically from
PTPase-inactive SHP-2–expressing cells (Fig. 2 B) and,
second, the phosphotyrosine immunoblotting signal de-
rived from p110 was significantly stronger when the pro-
tein was coprecipitated with inactive compared with wild-
type SHP-2 (Fig. 3, A and B). A parallel situation is found
in the Drosophila system, in which Dos has been shown to
be a substrate for the SHP-2 homologue csw (34).
PTPase actions on p110 may cause the release of signaling
molecules from the complex, either by direct dephosphory-
lation of a binding site or due to a dephosphorylation-related
conformational change. Molecules such as PI 39-kinase
may therefore use p110 as a means of transportation from
the cytosol to a specific membrane proximal compartment for
interaction with their substrates. SHP-2–mediated regulation
of the phosphotyrosine content of p110 could then result in
the release and/or activation of PI 39-kinase at its appropri-
ate site of action. A molecular link between PI 39-kinase
and small GTP-binding proteins such as Ras was originally
made by Rodriguez-Viciana et al. (43). More recent re-
ports provide evidence for the positive regulation of gua-
nine nucleotide exchange factor proteins by PI 39-kinase as
Figure 5. PI 39-kinase, SHP-2, and p110 tyrosine phosphoprotein
form a complex in TCR-activated Jurkat T cells. (A) Parental Jurkat T
cells were stimulated for 1 min with 1 mg/ml OKT3 and lysed. The re-
sulting lysates were subjected to two rounds of precipitation with preim-
mune or p85 PI 39-kinase (p85) antisera followed by immunoprecipita-
tion of SHP-2. The resulting precipitates and sample aliquots of control
or p85-depleted lysates (105 cell equivalents) were analyzed by SDS-
PAGE and immunoblotted for phosphotyrosine (top) and then reprobed
for SHP-2 (bottom). (B) pZEM neo C®S SHP-2 (lanes 3 and 4) and
empty vector transfectants (lanes 1 and 2) were incubated for 5 h in the
presence of 10 mM of cadmium and then left untreated or stimulated for 1
min with OKT3 (0.5 mg/ml) and lysed. The resulting lysates were immu-
noprecipitated for p85 PI 39-kinase. The precipitates were analyzed on
SDS-PAGE and immunoblotted for phosphotyrosine (top) and reprobed
for p85 (middle) and SHP-2 (bottom).
Figure 6. A model to illustrate how SHP-2 regulates coupling of the
TCR to the Ras/MAPK pathway. Ligation of the TCR induces the ty-
rosine phosphorylation of cytosolic p110 and membrane-localized p36.
This results in the formation of a cytosolic complex containing SHP-2, PI
39-kinase, and Grb-2. Grb-2 may then mediate the association of this
complex with the membrane via p36 binding. Arrival at the membrane
causes full activation of SHP-2, resulting in the dephosphorylation of
p110 and p36. Promotion of the Ras/MAPK pathway ensues, possibly
due to the release and subsequent activation of PI 39-kinase.1425 Frearson and Alexander
a result of the binding of phosphatidylinositol (3,4,5) tris-
phosphate, the product of PI 39-kinase action, to their
pleckstrin homology domains (44, 45). PI 39-kinase may
therefore provide a link between the dephosphorylating ac-
tions of SHP-2 and the positive role played by this PTPase
in coupling TCR stimulation to the Ras/MAPK pathway.
We have also demonstrated the enhanced phosphotyrosine
signal of the Grb-2 binding protein p36 protein in mem-
branes expressing mutant SHP-2 (Figs. 2 B and 3 B), the
significance of which will become apparent with a clearer
understanding of p36 structure and function.
In conclusion, we have shown the PTPase SHP-2 to be
an important component of a signaling complex that regu-
lates the MAPK pathway in human T cells. The mode of
action of SHP-2 in promoting the MAPK pathway is likely
to involve the dephosphorylation of at least two mem-
brane-associated tyrosine phosphoproteins, p36 and p110.
Future analysis of p36 and identification of p110 will be
necessary to define more precisely how SHP-2 is involved
in the regulation of TCR-induced MAPK activation and
perhaps in other T cell signal transduction pathways.
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